Euclidean Capital
Latest statistics and disclosures from Euclidean Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are SPY, GLD, INDA, RAPT, ALEC, and represent 95.30% of Euclidean Capital's stock portfolio.
- Added to shares of these 3 stocks: SPY (+$319M), GLD (+$63M), SRZN.
- Started 1 new stock position in SRZN.
- Reduced shares in these 1 stock: Surrozen.
- Sold out of its position in Surrozen.
- Euclidean Capital was a net buyer of stock by $382M.
- Euclidean Capital has $889M in assets under management (AUM), dropping by -3.05%.
- Central Index Key (CIK): 0001825034
Tip: Access up to 7 years of quarterly data
Positions held by Euclidean Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Euclidean Capital
Euclidean Capital holds 13 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr S&p 500 Etf Tr Tr Unit (SPY) | 49.1 | $436M | +272% | 917k | 475.31 |
|
| Spdr Gold Tr Gold Shs (GLD) | 29.9 | $266M | +30% | 1.4M | 191.17 |
|
| Ishares Tr Msci India Etf (INDA) | 13.3 | $118M | 2.4M | 48.81 |
|
|
| Rapt Therapeutics (RAPT) | 1.8 | $16M | 658k | 24.85 |
|
|
| Alector (ALEC) | 1.2 | $10M | 1.3M | 7.98 |
|
|
| Foghorn Therapeutics (FHTX) | 1.1 | $10M | 1.6M | 6.45 |
|
|
| 23andme Holding Class A Com (ME) | 1.1 | $9.4M | 10M | 0.91 |
|
|
| Oric Pharmaceuticals (ORIC) | 1.0 | $9.1M | 989k | 9.20 |
|
|
| Pmv Pharmaceuticals (PMVP) | 0.9 | $8.1M | 2.6M | 3.10 |
|
|
| Tenaya Therapeutics (TNYA) | 0.4 | $3.3M | 1.0M | 3.24 |
|
|
| Ngm Biopharmaceuticals (NGM) | 0.1 | $852k | 992k | 0.86 |
|
|
| Surrozen Com New (SRZN) | 0.1 | $824k | NEW | 88k | 9.40 |
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $3.3k | 171k | 0.02 |
|
Past Filings by Euclidean Capital
SEC 13F filings are viewable for Euclidean Capital going back to 2020
- Euclidean Capital 2023 Q4 filed Feb. 14, 2024
- Euclidean Capital 2023 Q3 amended filed Dec. 1, 2023
- Euclidean Capital 2023 Q3 filed Nov. 14, 2023
- Euclidean Capital 2023 Q2 filed Aug. 14, 2023
- Euclidean Capital 2023 Q1 filed May 15, 2023
- Euclidean Capital 2022 Q4 filed Feb. 14, 2023
- Euclidean Capital 2022 Q3 filed Nov. 14, 2022
- Euclidean Capital 2022 Q2 filed Aug. 15, 2022
- Euclidean Capital 2022 Q1 filed May 16, 2022
- Euclidean Capital 2021 Q4 filed Feb. 14, 2022
- Euclidean Capital 2021 Q2 restated filed Nov. 15, 2021
- Euclidean Capital 2021 Q3 filed Nov. 15, 2021
- Euclidean Capital 2021 Q2 filed Aug. 16, 2021
- Euclidean Capital 2021 Q1 filed May 17, 2021
- Euclidean Capital 2020 Q4 filed Feb. 12, 2021